2020
DOI: 10.7759/cureus.8102
|View full text |Cite
|
Sign up to set email alerts
|

Flexural Exanthema From Enfortumab Vedotin

Abstract: Urothelial malignancies are commonly treated with platinum-based therapies. Newer trials have tested antimitotic therapies such as enfortumab vedotin as viable treatment therapy for refractory malignany. Enfortumab vedotin targets nectin-4, a member of a family of calcium-dependent, immunoglobulin-like adhesion molecules found in adherens junctions and expressed in various epithelial malignancies, including bladder, breast, lung, ovarian, head/neck, and esophageal cancers. We present a case of a patient with s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(11 citation statements)
references
References 3 publications
0
11
0
Order By: Relevance
“…26 Varying degrees of rash and severe eczematoid and lichenoid eruption are rather unusual, especially the cases with full-thickness epidermal necrosis or symmetrical drug-related intertriginous and flexural exanthema and are successfully treated with moisturizing agents and oral or topical corticosteroids. 27,28 In this changing treatment landscape, there is great opportunity to develop and validate predictive biomarkers that can identify patients who are most likely to benefit from a particular therapy. 29 Moreover, the optimal selection of best candidates for EV treatment remains a real challenge, while target expression and its biological factors such as selectivity, heterogeneity, internalization rate and functional role, are crucial in order to properly…”
Section: Expert Opinionmentioning
confidence: 99%
See 1 more Smart Citation
“…26 Varying degrees of rash and severe eczematoid and lichenoid eruption are rather unusual, especially the cases with full-thickness epidermal necrosis or symmetrical drug-related intertriginous and flexural exanthema and are successfully treated with moisturizing agents and oral or topical corticosteroids. 27,28 In this changing treatment landscape, there is great opportunity to develop and validate predictive biomarkers that can identify patients who are most likely to benefit from a particular therapy. 29 Moreover, the optimal selection of best candidates for EV treatment remains a real challenge, while target expression and its biological factors such as selectivity, heterogeneity, internalization rate and functional role, are crucial in order to properly…”
Section: Expert Opinionmentioning
confidence: 99%
“… 26 Varying degrees of rash and severe eczematoid and lichenoid eruption are rather unusual, especially the cases with full-thickness epidermal necrosis or symmetrical drug-related intertriginous and flexural exanthema and are successfully treated with moisturizing agents and oral or topical corticosteroids. 27 , 28 …”
Section: Expert Opinionmentioning
confidence: 99%
“…1 Approximately 45% of patients in EV phase I clinical trials experienced rash as an adverse event, 1 but only a few case reports describe variable clinicopathologic presentations. [2][3][4] We therefore sought to further characterize the distinctive clinical and histopathologic features of EV-associated cutaneous toxicity.…”
Section: Clinicopathologic Characterization Of Enfortumab Vedotin-ass...mentioning
confidence: 99%
“…1,2 For evaluating cellulitis, the Infectious Disease Society of America (IDSA) recommends imaging for patients with febrile neutropenia and blood cultures for patients with immunocompromised states, malignancy, signs of systemic infection, or animal bites. 3 This study investigates blood cultures and imaging for cellulitis in hospitalized pediatric patients.…”
Section: J Am Acad Dermatolmentioning
confidence: 99%
“…The drug has been demonstrated to have a significant response rate in early phase trials and is known for its tolerable side-effect profile (7)(8)(9)(10)(11). Common toxicities that have been attributed to EV were fatigue, peripheral neuropathy, skin rashes, gastrointestinal issues, and hematological suppression (12). The first case of cutaneous toxicities induced by EV was found in 2019 (13).…”
Section: Introductionmentioning
confidence: 99%